Tradestie Institutional Equity Comparison Engine

PCVX vs LEGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LEGN Overall Edge

LEGN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Legend Biotech Corporation American Depositary Shares (LEGN) driven by superior Valuation, Growth & Margin while PCVX counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, PCVX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LEGN at 27.5x Forward P/E and 2.8% operating margin (+32.0% YoY). In options structure, PCVX sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against LEGN sits in UNCLASSIFIED (24th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LEGN
PCVX N/M vs LEGN 27.5x Fwd P/E
Growth & Margin Winner LEGN
Op Margin 0.0% vs 2.8% ยท YoY +0.0% vs +32.0%
Momentum & Technical Winner PCVX
1Y +36.2% vs -47.5% ยท 52W Pos 41% vs 0%
Options & Structure Winner PCVX
CONSOLIDATION (10th %ile IV) vs UNCLASSIFIED (24th %ile IV)
PCVX NASDAQ
Vaxcyte, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$62.04
-2.1% 1D
Market Cap $10.2B
1M Return -2.48%
1Y Return +36.2%
Forward P/E N/M
Unified AI Score
47.3 / 100 HOLD
Tech 42.0 Fund 50.0 Flow 65.0 Mom 50.0
LEGN NASDAQ
Legend Biotech Corporation American Depositary Shares
Pharmaceutical Preparations
$16.30
-6.89% 1D
Market Cap $3.6B
1M Return -11.82%
1Y Return -47.45%
Forward P/E 27.5x
Unified AI Score
42.8 / 100 HOLD
Tech 27.0 Fund 45.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PCVX +36.2% LEGN -47.45% Spread: +83.65 pp (PCVX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PCVX TTM Op. Margin: 0.0% LEGN TTM Op. Margin: 2.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PCVX vs LEGN. Trailing 12-month operating profitability (PCVX 0.0% vs LEGN 2.8%) and valuation multiples (PCVX N/M vs LEGN 27.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PCVX (4) vs LEGN (5)
Institutional Metric PCVX LEGN Criterion Row Winner
Market Capitalization Scale $10.2B $3.6B Larger Scale PCVX
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple LEGN
Forward P/E Ratio Valuation N/M 27.5x Lower Multiple LEGN
Revenue Growth (YoY) Growth +0.0% +32.0% Higher Growth LEGN
Operating Margin (TTM) Profitability 0.0% 2.8% Higher Margin LEGN
Net Profit Margin Profitability 0.0% -0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -42.7% -0.0% Higher ROE LEGN
52-Week Range Position Momentum 41% ($42โ€“$91) 0% ($16โ€“$38) Stronger Trend PCVX
Beta / 30D Volatility Risk Regime 1.29ฮฒ ยท 57% Vol 1.02ฮฒ ยท 83% Vol Lower Realized Risk PCVX
Unified Institutional Score Composite Signal 47.3 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite PCVX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PCVX vs LEGN Buy Guide
PCVX CONSOLIDATION
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live PCVX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LEGN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live LEGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PCVX nor LEGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.